At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics https://t.co/IaJ1gyECZu

Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886

#OP089 at #EULAR2026 provides real-world data on biologic use after new cancer diagnoses in RA. Continuing biologics in early-stage cancer, & restarting them in many stage 2-3 cancers, was not associated with worse 5-year survival in this Japanese registry study. @RheumNow https://t.co/OdCPiCxFEq

#EULAR2025 OP0127 Still trying to get my head around the flat line PBO response. In Sjogren pts with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met all endpoints. ESSPRI improved too! Could be because strict concom DMARD inc. GC protocol @RheumNow https://t.co/FEhXfNPvfG

In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV

#Autoimmune #progressive #pulmonary #fibrosis Large Spanish registry ❎more mortality if not on #DMARDs ?underRx of proven #Rx with #antifibrotics Median survival post #dx #PPF 7.8 yrs Can we do better? #ABST POS0430 @RheumNow #EULAR2026 https://t.co/gP7apxfEPS

Multiparametric renal MRI in LN: Structural MRI can differentiate bet. active and stable dse Exudative = active inflamm In quanti analysis, low ADC values may reflect fibrosis. A potential non-invasive biomarker? OP092 @rheumNow #EULAR2026 https://t.co/IarTGOen7v

DIPSA RCT: diet in PsA 92 pts 3 arms Mediterranean vs DASH low-calorie vs standard advice Primary takeaway: amount of weight loss matters more than diet! -All groups lost modest weight 1–2.5 kg -All improved similarly in DAPSA -4 to -6 wk 24 -No differences for disease https://t.co/U0cxtdl2Yb

This retrospective cohort of NPSLE pts showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI Pts w/ diffuse symptoms - normal MRI except brain atrophy Interesting to know how this can aid in future mgt strategies for NPSLE OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK